Efficacy and Safety of Sintilimab and Nab-paclitaxel in Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma Patients With Progression After Fluoropyrimidine or Platinum, a Multi-center, Phase II, Single Arm Trial
Latest Information Update: 05 Jul 2024
At a glance
- Drugs Paclitaxel (Primary) ; Sintilimab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Jun 2024 Results (n=58) assessing efficacy, survival outcomes and exploration of biological markerspresented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 09 Mar 2022 Planned End Date changed from 30 Oct 2022 to 1 Feb 2023.
- 09 Mar 2022 Planned primary completion date changed from 30 Dec 2021 to 30 Aug 2022.